Journal
CLINICAL ONCOLOGY
Volume 25, Issue 5, Pages 275-282Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.clon.2013.01.007
Keywords
Breast cancer; DCIS; ductal carcinoma in situ
Categories
Ask authors/readers for more resources
The incidence of ductal carcinoma in situ (DCIS) has increased in recent decades, primarily due to the widespread implementation of breast cancer screening. Traditionally, the management of DCIS has mirrored that of invasive breast cancer, with a focus on adequate surgical excision, breast-conserving surgery, adjuvant radiotherapy and endocrine therapy. However, an increasing understanding of the biology of this spectrum of conditions many mean that some cases may be managed more conservatively, reserving aggressive therapies for those patients at high risk of progression to invasive disease, ultimately aiming for a personalised approach based on individual risk factors. This overview highlights the key evidence behind current practice and discusses the rationale for current and future clinical trials in DCIS. (c) 2013 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available